Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Benitec Biopharma's Enterprise Value is $75.11 Mil.
Benitec Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-21.67 Mil. Therefore, Benitec Biopharma's EV-to-EBIT ratio for today is -3.47.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Benitec Biopharma's Enterprise Value is $75.11 Mil.
Benitec Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-21.33 Mil. Therefore, Benitec Biopharma's EV-to-EBITDA ratio for today is -3.52.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Benitec Biopharma's Enterprise Value is $75.11 Mil.
Benitec Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01 Mil. Therefore, Benitec Biopharma's EV-to-Revenue ratio for today is 10,729.71.
Benitec Biopharma Enterprise Value Historical Data
The historical data trend for Benitec Biopharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Benitec Biopharma's Enterprise Value
For the Biotechnology subindustry, Benitec Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's Enterprise Value falls into.
Benitec Biopharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Benitec Biopharma's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma (NAS:BNTC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Benitec Biopharma's current Enterprise Value is $75.11 Mil.
Benitec Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.67 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Benitec Biopharma's current Enterprise Value is $75.11 Mil.
Benitec Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.33 Mil.
Benitec Biopharma's current Enterprise Value is $75.11 Mil.
Benitec Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of Benitec Biopharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Benitec Biopharma (Benitec Biopharma) Business Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNTC has been successfully added to your 